{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:41:06Z","timestamp":1783122066789,"version":"3.54.6"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41409-018-0112-x","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T16:37:16Z","timestamp":1517848636000},"page":"942-945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation"],"prefix":"10.1038","volume":"53","author":[{"given":"Alisha","family":"Pandit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houry","family":"Leblebjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-8734","authenticated-orcid":false,"given":"Francisco M.","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"112_CR1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/blood.V84.2.657.657","volume":"84","author":"P Ljungman","year":"1994","unstructured":"Ljungman P, Lewensohn-Fuchs I, Hammarstr\u00f6m V, Aschan J, Brandt L, Bolme P, et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood. 1994;84:657\u201363. http:\/\/www.bloodjournal.org\/content\/84\/2\/657.abstract.","journal-title":"Blood"},{"key":"112_CR2","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jama.1992.03480090085032","volume":"267","author":"LJ Kaplan","year":"1992","unstructured":"Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA. 1992;267:1237\u201341.","journal-title":"JAMA"},{"key":"112_CR3","first-page":"427","volume":"9","author":"K Pauksen","year":"1992","unstructured":"Pauksen K, Duraj V, Ljungman P, Sj\u00f6lin J, Oberg G, L\u00f6nnerholm G, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant. 1992;9:427\u201332. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1628126.","journal-title":"Bone Marrow Transplant"},{"key":"112_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0025-7753(02)73434-9","volume":"119","author":"C Adell","year":"2002","unstructured":"Adell C, Bayas JM, Vilella A, Perales M, Vidal J, Bertran MJ, et al. Post-transplantation vaccination of bone-marrow transplant recipients. Med Clin. 2002;119:405\u20139.","journal-title":"Med Clin"},{"key":"112_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/jmv.24621","volume":"89","author":"N Inazawa","year":"2017","unstructured":"Inazawa N, Hori T, Nojima M, Saito M, Igarashi K, Yamamoto M, et al. Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay. J Med Virol. 2017;89:358\u201362.","journal-title":"J Med Virol"},{"key":"112_CR6","first-page":"277","volume":"13","author":"CS Han","year":"1994","unstructured":"Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant. 1994;13:277\u201383. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8199570.","journal-title":"Bone Marrow Transplant"},{"key":"112_CR7","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271\u201384. http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMoa051016.","journal-title":"N Engl J Med"},{"key":"112_CR8","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2007-03-077644","volume":"110","author":"V Erard","year":"2007","unstructured":"Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers MED, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. 2007;110:3071\u20137.","journal-title":"Blood"},{"key":"112_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309\u201318.","journal-title":"Clin Infect Dis"},{"key":"112_CR10","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","volume":"18","author":"K Noonan","year":"2012","unstructured":"Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, et al. Lenalidomide-induced immunomodulation in multiple myeloma: Impact on vaccines and antitumor responses. Clin Cancer Res. 2012;18:1426\u201334.","journal-title":"Clin Cancer Res"},{"key":"112_CR11","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907\u201316.","journal-title":"Blood"},{"key":"112_CR12","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389. http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.72.6679.","journal-title":"J Clin Oncol"},{"key":"112_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bbmt.2013.11.013","volume":"20","author":"NC Issa","year":"2014","unstructured":"Issa NC, Marty FM, Leblebjian H, Galar A, Shea MM, Antin JH, Soiffer RJ, Baden LR. Live-attenuated varicella zoster vaccine in hematopoietic stem-cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20:285\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"112_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-065X.1997.tb00975.x","volume":"157","author":"R Parkman","year":"1997","unstructured":"Parkman R, Weinberg KI. Immunological reconstitution following bone marrow transplantation. Immunol Rev. 1997;157:73\u20138.","journal-title":"Immunol Rev"},{"key":"112_CR15","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","volume":"26","author":"A Chanan-Khan","year":"2008","unstructured":"Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26:4784\u201390.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0112-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0112-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0112-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T06:12:57Z","timestamp":1659075177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0112-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["112"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0112-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]},"assertion":[{"value":"1 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PGR has received research funding from Takeda, BMS, and Celgene; serves on advisory boards for Takeda, Janssen, and Celgene. FMM has received research funding from Astellas, Chimerix, Merck, and Shire; and consulting honoraria from Alexion, Chimerix, LFB, Roche Molecular Diagnostics, and Shire. NCI has received research funding from Astellas and Merck and consulting honoraria from Akros Pharma. The remaining authors AP, HL, SPH, JPL, and LRB declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}